NCT01394926View on ClinicalTrials.gov

Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Carotid Artery Disease
Interventions
DRUG

Optison

Optison is a sterile non-pyrogenic suspension of perflutren for IV administration.

Trial Locations (1)

08540

GE Healthcare, Princeton

Sponsors

Lead Sponsor

GE Healthcare
All Listed Sponsors
lead

GE Healthcare

INDUSTRY

NCT01394926 - Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease | Biotech Hunter | Biotech Hunter